Author's response to reviews

Title: APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.

Authors:

Russell D Petty (r.d.petty@abdn.ac.uk)
Leslie M Samuel (l.samuel@nhs.net)
Graeme I Murray (g.i.murray@abdn.ac.uk)
Graham Macdonald (graham.macdonald@nhs.net)
Terry O'Kelly (tokelly@nhs.net)
Malcom Loudon (malcolm.loudon@arh.grampian.scot.nhs.uk)
Norman Binnie (Norman.Binnie@NHS.net)
Emad Aly (emad.aly@nhs.net)
Aileen Mckinley (aileen.mckinley@nhs.net)
Weiguang Wang (w.wang2@wlv.ac.uk)
Fiona Gilbert (f.j.gilbert@abdn.ac.uk)
Scott Semple (scott.semple@ed.ac.uk)
Elaina Collie-duguid (e.collie-duguid@abdn.ac.uk)

Version: 3 Date: 12 November 2009

Author's response to reviews: see over
Dear Andrea Bucceri,

MS: 1163450623266366

APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.


Thank for your recent correspondence accepting this manuscript for publication in BMC cancer, subject to the following:

‘we need you to specify in the method section of the manuscript whether you have obtained informed consent from the patients for the use and publication of the data’

This issue has been addressed in the revised manuscript enclosed by the addition of the following statement on page 6 in the METHODS sections, Patients, Follow up and Treatment subsection, second sentence:

‘Patients provided informed consent in accordance with the regulations and instruction of the North of Scotland Research Ethics Committee for study participation, including use and publication of results’

I hope that this meets with your approval. Please do not hesitate to contact myself if you have any queries or require further information.

I look forward to hearing from you

Yours sincerely

Dr Russell D Petty
(on behalf of all submitting authors)